89 related articles for article (PubMed ID: 15566305)
1. Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
Bilodeau MT; Balitza AE; Koester TJ; Manley PJ; Rodman LD; Buser-Doepner C; Coll KE; Fernandes C; Gibbs JB; Heimbrook DC; Huckle WR; Kohl N; Lynch JJ; Mao X; McFall RC; McLoughlin D; Miller-Stein CM; Rickert KW; Sepp-Lorenzino L; Shipman JM; Subramanian R; Thomas KA; Wong BK; Yu S; Hartman GD
J Med Chem; 2004 Dec; 47(25):6363-72. PubMed ID: 15566305
[TBL] [Abstract][Full Text] [Related]
2. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
[TBL] [Abstract][Full Text] [Related]
3. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
4. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
[TBL] [Abstract][Full Text] [Related]
5. Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
Sisko JT; Tucker TJ; Bilodeau MT; Buser CA; Ciecko PA; Coll KE; Fernandes C; Gibbs JB; Koester TJ; Kohl N; Lynch JJ; Mao X; McLoughlin D; Miller-Stein CM; Rodman LD; Rickert KW; Sepp-Lorenzino L; Shipman JM; Thomas KA; Wong BK; Hartman GD
Bioorg Med Chem Lett; 2006 Mar; 16(5):1146-50. PubMed ID: 16368234
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding.
Fraley ME; Arrington KL; Buser CA; Ciecko PA; Coll KE; Fernandes C; Hartman GD; Hoffman WF; Lynch JJ; McFall RC; Rickert K; Singh R; Smith S; Thomas KA; Wong BK
Bioorg Med Chem Lett; 2004 Jan; 14(2):351-5. PubMed ID: 14698157
[TBL] [Abstract][Full Text] [Related]
7. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.
Lin H; Yamashita DS; Xie R; Zeng J; Wang W; Leber J; Safonov IG; Verma S; Li M; Lafrance L; Venslavsky J; Takata D; Luengo JI; Kahana JA; Zhang S; Robell KA; Levy D; Kumar R; Choudhry AE; Schaber M; Lai Z; Brown BS; Donovan BT; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):684-8. PubMed ID: 20006500
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
9. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
Zhang P; Huang W; Wang L; Bao L; Jia ZJ; Bauer SM; Goldman EA; Probst GD; Song Y; Su T; Fan J; Wu Y; Li W; Woolfrey J; Sinha U; Wong PW; Edwards ST; Arfsten AE; Clizbe LA; Kanter J; Pandey A; Park G; Hutchaleelaha A; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2009 Apr; 19(8):2179-85. PubMed ID: 19297154
[TBL] [Abstract][Full Text] [Related]
10. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor.
Cid JM; Tresadern G; Vega JA; de Lucas AI; Matesanz E; Iturrino L; Linares ML; Garcia A; Andrés JI; Macdonald GJ; Oehlrich D; Lavreysen H; Megens A; Ahnaou A; Drinkenburg W; Mackie C; Pype S; Gallacher D; Trabanco AA
J Med Chem; 2012 Oct; 55(20):8770-89. PubMed ID: 23072213
[TBL] [Abstract][Full Text] [Related]
12. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
Ruel R; Thibeault C; L'Heureux A; Martel A; Cai ZW; Wei D; Qian L; Barrish JC; Mathur A; D'Arienzo C; Hunt JT; Kamath A; Marathe P; Zhang Y; Derbin G; Wautlet B; Mortillo S; Jeyaseelan R; Henley B; Tejwani R; Bhide RS; Trainor GL; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 May; 18(9):2985-9. PubMed ID: 18395443
[TBL] [Abstract][Full Text] [Related]
13. Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors.
Ioannidis S; Lamb ML; Almeida L; Guan H; Peng B; Bebernitz G; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1669-73. PubMed ID: 20144546
[TBL] [Abstract][Full Text] [Related]
14. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
[TBL] [Abstract][Full Text] [Related]
15. 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.
Micheli F; Bonanomi G; Blaney FE; Braggio S; Capelli AM; Checchia A; Curcuruto O; Damiani F; Fabio RD; Donati D; Gentile G; Gribble A; Hamprecht D; Tedesco G; Terreni S; Tarsi L; Lightfoot A; Stemp G; Macdonald G; Smith A; Pecoraro M; Petrone M; Perini O; Piner J; Rossi T; Worby A; Pilla M; Valerio E; Griffante C; Mugnaini M; Wood M; Scott C; Andreoli M; Lacroix L; Schwarz A; Gozzi A; Bifone A; Ashby CR; Hagan JJ; Heidbreder C
J Med Chem; 2007 Oct; 50(21):5076-89. PubMed ID: 17867665
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
17. Initial SAR studies on apamin-displacing 2-aminothiazole blockers of calcium-activated small conductance potassium channels.
Gentles RG; Grant-Young K; Hu S; Huang Y; Poss MA; Andres C; Fiedler T; Knox R; Lodge N; Weaver CD; Harden DG
Bioorg Med Chem Lett; 2008 Oct; 18(19):5316-9. PubMed ID: 18774291
[TBL] [Abstract][Full Text] [Related]
18. Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.
Plowright AT; Nilsson K; Antonsson M; Amin K; Broddefalk J; Jensen J; Lehmann A; Jin S; St-Onge S; Tomaszewski MJ; Tremblay M; Walpole C; Wei Z; Yang H; Ulander J
J Med Chem; 2013 Jan; 56(1):220-40. PubMed ID: 23227781
[TBL] [Abstract][Full Text] [Related]
19. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.
Bavetsias V; Large JM; Sun C; Bouloc N; Kosmopoulou M; Matteucci M; Wilsher NE; Martins V; Reynisson J; Atrash B; Faisal A; Urban F; Valenti M; de Haven Brandon A; Box G; Raynaud FI; Workman P; Eccles SA; Bayliss R; Blagg J; Linardopoulos S; McDonald E
J Med Chem; 2010 Jul; 53(14):5213-28. PubMed ID: 20565112
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]